First in 35 years: Patient’s own insulin returns

After receiving gene-edited donor islet cells without any immunosuppressive drugs, a 42-year-old man with type 1 diabetes has produced his own insulin, potentially paving the way for curative therapy. The engineered cells functioned for 12 weeks in early testing, showing meal-responsive insulin secretion and improved glucose control.

Clinicians at Uppsala University Hospital implanted the modified cells into the patient’s forearm muscle, a practical site that enables noninvasive imaging and sampling. The result suggests a path past the dual hurdles of immune rejection and the autoimmune attack that define this disease.

What the first-in-human result shows

The transplanted cells restored C-peptide production, a biomarker of endogenous insulin, in a person living with type 1 diabetes for 37 years. The signal emerged within weeks and persisted through the 12-week evaluation window, indicating functional beta-cell activity under daily conditions.

The patient required no anti-rejection medicines, avoiding the infection and toxicity risks that have long constrained islet transplantation. While the dose was intentionally subtherapeutic, the functional readout supports scaling to therapeutic levels in subsequent cohorts.

Did you know?
Islet transplants have restored insulin in patients before, but typically require lifelong immunosuppression, which raises infection risk and can damage kidney function.

How gene editing enabled immune evasion

Researchers used a CRISPR-based approach to create ‘hypoimmune’ islets that avoid immune detection. Edits disrupt key immune recognition pathways while overexpressing CD47, a surface signal that tells immune cells not to attack, improving graft survival without systemic drugs.

This stealth profile aims to sidestep both allogeneic rejection and autoimmune targeting seen in type 1 diabetes. Early human data align with preclinical models, suggesting a platform that could be applied to multiple cell types and conditions.

Why the forearm muscle matters

Implanting the islets in the forearm muscle allows clinicians to track grafts with MRI and evaluate local responses more readily than traditional intrahepatic sites. It also simplifies potential biopsies and standardized assessments in early-stage trials.

The site showed stable engraftment and glucose-responsive insulin secretion. This operational visibility is valuable as developers refine dose, vascularization strategies, and device-free delivery methods for broader clinical use.

ALSO READ | How a common skin virus can flip a switch to cancer

Safety, dose, and next steps

The study focused on safety and feasibility, using only a fraction of the cells needed for full insulin independence. No serious adverse events were reported during the 12-week period, supporting dose escalation with careful monitoring in upcoming phases.

Larger trials will test therapeutic cell numbers, durability beyond three months, and consistency across diverse patient profiles. Key endpoints include reduced exogenous insulin use, time-in-range gains, and protection against hypoglycemia.

The road to scalable therapy

A major constraint for classic islet transplantation is donor scarcity and mandatory immunosuppression. Pairing immune-evasion edits with stem cell manufacturing could provide a standardized, off-the-shelf product supply for broader access.

Developers aim to demonstrate reproducible potency, long-term graft health, and manufacturing quality controls. Success could open a path to regulatory approvals for chronic cell replacement across endocrinology and beyond.

Context from recent advances

This result follows a year of progress in cell therapy for diabetes, including stem cell-derived islets enabling insulin independence in small cohorts. What distinguishes this milestone is donor-cell survival without immunosuppression, addressing a central limitation of prior approaches.

Future studies will compare edited donor cells with autologous or stem-derived products, optimizing for durability, safety, and cost. Converging strategies may ultimately yield hybrid solutions tailored to patient-specific needs.

Outlook: toward durable insulin independence

The early human proof-of-concept indicates that immune-evasive engineering can deliver functional insulin without systemic drugs. Larger trials could meet durability and dosing targets, potentially transitioning type 1 diabetes care from lifelong management to restorative, one-time interventions.